Want to see BFRI full AI Analyst Report?
BFRI Stock Chart & Stats
$1.49
-$0.01(-0.92%)
At close: 4:00 PM EDT
$1.49
-$0.01(-0.92%)
Day’s Range― - ―
52-Week Range$0.55 - $1.63
Previous CloseN/A
Volume7.39K
Average Volume (3M)552.92K
Market Cap
$22.43M
Enterprise Value$15.06
Total Cash (Recent Filing)$4.67M
Total Debt (Recent Filing)$7.50M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 18, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding14,852,359
10 Day Avg. Volume592,246
30 Day Avg. Volume552,925
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.55
Price to Sales (P/S)0.14
P/FCF Ratio-0.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$45.65M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsData from the Phase 3 extremities trial and the Phase 2b acne trial expected early in 2026 could validate new indications and materially expand commercial opportunity.
Operational Cost SavingsRestructuring of agreements with former parent Biofrontera AG is expected to deliver cost savings and operational efficiencies that improve margins and cash flow flexibility.
Regulatory FilingA supplemental NDA submission for the extremities indication projected in mid-2026 could enable label expansion and broader prescribing, supporting future revenue growth.
Bears Say
Demand Timing VolatilityCustomer stockpiling ahead of an anticipated price increase could create a pull-forward effect, producing revenue volatility once the stocking period ends.
Profitability PressureA larger-than-planned net loss underscores ongoing profitability challenges that could weigh on the stock until margins show sustained improvement.
Top-line Momentum RiskIn-line quarterly revenue suggests limited top-line momentum, increasing the risk that growth expectations may not be met.
Biofrontera News
BFRI FAQ
What was Biofrontera’s price range in the past 12 months?
Biofrontera lowest stock price was $0.55 and its highest was $1.63 in the past 12 months.
What is Biofrontera’s market cap?
Biofrontera’s market cap is $22.43M.
When is Biofrontera’s upcoming earnings report date?
Biofrontera’s upcoming earnings report date is Nov 18, 2026 which is in 74 days.
How were Biofrontera’s earnings last quarter?
Biofrontera released its earnings results on Aug 13, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.055.
Is Biofrontera overvalued?
According to Wall Street analysts Biofrontera’s price is currently Overvalued.
Does Biofrontera pay dividends?
Biofrontera does not currently pay dividends.
What is Biofrontera’s EPS estimate?
Biofrontera’s EPS estimate is -0.22.
How many shares outstanding does Biofrontera have?
Biofrontera has 14,852,359 shares outstanding.
What happened to Biofrontera’s price movement after its last earnings report?
Biofrontera reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went up 0.8%.
Which hedge fund is a major shareholder of Biofrontera?
Currently, no hedge funds are holding shares in BFRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and commercial momentum: double-digit revenue growth, substantial gross margin expansion, marked improvement in adjusted EBITDA, and clear near-term clinical catalysts (sBCC PDUFA and AK label expansion) that leverage the existing installed base. Key risks include an adverse ITC ruling temporarily restricting sales to accounts with the RhodoLED XL (affecting a meaningful minority of lamps), the need for border approval of a remedial lamp design, and a modest cash position with a going concern disclosure that may require additional financing. On balance, the positive operational trends and pipeline catalysts outweigh the near-term legal and liquidity headwinds, but successful remediation, timely approvals, and working capital execution remain critical.View all BFRI earnings summariesTechnical Analysis
Ownership Overview
3.76% Insiders
0.77% Mutual Funds
13.57% Other Institutional Investors
81.41% Public Companies and
Individual Investors